[{"address1": "201 Haskins Way", "address2": "Suite 230", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "215 731 9450", "website": "https://www.cero.bio", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies. The company was incorporated in 2021 and is based in South San Francisco, California.", "fullTimeEmployees": 8, "companyOfficers": [{"maxAge": 1, "name": "Dr. Daniel Mark Corey M.D.", "age": 44, "title": "Founder, CTO & Director", "yearBorn": 1979, "fiscalYear": 2023, "totalPay": 376035, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brian G. Atwood", "age": 70, "title": "President, CEO & Chairman", "yearBorn": 1953, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Charles Ross Carter", "age": 55, "title": "CFO, Treasurer & Corporate Secretary", "yearBorn": 1968, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.9197, "open": 0.9134, "dayLow": 0.8901, "dayHigh": 0.9395, "regularMarketPreviousClose": 0.9197, "regularMarketOpen": 0.9134, "regularMarketDayLow": 0.8901, "regularMarketDayHigh": 0.9395, "beta": -0.056, "volume": 28760, "regularMarketVolume": 28760, "averageVolume": 1105163, "averageVolume10days": 59470, "averageDailyVolume10Day": 59470, "bid": 0.8503, "ask": 0.9389, "bidSize": 100, "askSize": 100, "marketCap": 13629875, "fiftyTwoWeekLow": 0.87, "fiftyTwoWeekHigh": 12.8, "fiftyDayAverage": 1.44744, "twoHundredDayAverage": 7.314485, "currency": "USD", "enterpriseValue": 21038578, "floatShares": 7350231, "sharesOutstanding": 15062300, "sharesShort": 95654, "sharesShortPriorMonth": 26840, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0064, "heldPercentInsiders": 0.43466, "heldPercentInstitutions": 0.28439, "shortRatio": 0.91, "shortPercentOfFloat": 0.0083, "impliedSharesOutstanding": 15062300, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -1825386, "52WeekChange": -0.91658986, "SandP52WeekChange": 0.24688339, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "CERO", "underlyingSymbol": "CERO", "shortName": "CERo Therapeutics Holdings, Inc", "longName": "CERo Therapeutics Holdings, Inc.", "firstTradeDateEpochUtc": 1638282600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "c96e7212-658f-3054-8625-d2aafea7c5eb", "messageBoardId": "finmb_1673740339", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.9049, "recommendationKey": "none", "totalCash": 4593103, "totalCashPerShare": 0.305, "totalDebt": 2563992, "quickRatio": 0.408, "currentRatio": 0.472, "returnOnAssets": -0.26864, "freeCashflow": 18078762, "operatingCashflow": -5166984, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-06"}]